林登湖实验室披露交易条款:Crossbridge Bio股东或可获得总计高达3亿美元对价

美股速递
Apr 14

根据林登湖实验室最新披露的交易协议条款,Crossbridge Bio公司的股东有望获得总额高达3亿美元的对价安排。该交易方案为生物技术领域的并购活动再添重要案例,凸显了创新药企的市场价值获得资本认可。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10